When we look at this rapidly evolving
space, what we see are four factors that
are leading to the rapid digitization of
pharma companies, CROS and biotech
organizations. The 1st is that precision
medicine, even outside of digital
pathology, is seeing an enormous amount
of investment and focus. There's a need
to treat the right patient with the right
drug and we finally have the capacity to
deliver against that. It's therefore
receiving a lot of additional attention.
Pharma companies are restructuring around
this concept. And it's supported by a
second convergence aspect here, which is
the rise in the next generation
therapies, novel approaches to targeting
individual patients or subpopulations of
patients with therapies that work
extremely well, better than the standard
of care for that targeted subpopulation.
In parallel, what we're also seeing
is a revolutionary leap forward in
artificial intelligence. We've seen more
advances in the last two years with
artificial intelligence than we did in
the prior 20, and it's reshaping how we
extract new insight and new information
from what's ultimately an explosion in
new high-value data
that's emerged from digitization of
histopathology from digital pathology
adoption. And in tandem, these four
pillars are reshaping drug discovery and
drug development.